ZA202210474B - Methods of treating sars-cov-2 infections - Google Patents
Methods of treating sars-cov-2 infectionsInfo
- Publication number
- ZA202210474B ZA202210474B ZA2022/10474A ZA202210474A ZA202210474B ZA 202210474 B ZA202210474 B ZA 202210474B ZA 2022/10474 A ZA2022/10474 A ZA 2022/10474A ZA 202210474 A ZA202210474 A ZA 202210474A ZA 202210474 B ZA202210474 B ZA 202210474B
- Authority
- ZA
- South Africa
- Prior art keywords
- cov
- infections
- methods
- treating sars
- sars
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063008486P | 2020-04-10 | 2020-04-10 | |
| US202063062599P | 2020-08-07 | 2020-08-07 | |
| PCT/US2021/026302 WO2021207443A1 (en) | 2020-04-10 | 2021-04-08 | Methods of treating sars-cov-2 infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202210474B true ZA202210474B (en) | 2025-12-17 |
Family
ID=75787221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2022/10474A ZA202210474B (en) | 2020-04-10 | 2022-09-21 | Methods of treating sars-cov-2 infections |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12605364B2 (https=) |
| EP (1) | EP4132518B1 (https=) |
| JP (1) | JP2023521163A (https=) |
| KR (1) | KR20230002371A (https=) |
| CN (1) | CN115361947A (https=) |
| AU (1) | AU2021253866A1 (https=) |
| BR (1) | BR112022020193A2 (https=) |
| CA (1) | CA3174710A1 (https=) |
| IL (1) | IL296517A (https=) |
| MX (1) | MX2022012705A (https=) |
| WO (1) | WO2021207443A1 (https=) |
| ZA (1) | ZA202210474B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021254415A1 (en) * | 2020-04-10 | 2022-10-20 | Eagle Pharmaceuticals, Inc. | Methods of treating Severe Acute Respiratory Syndrome |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY201417A (en) * | 2017-10-20 | 2024-02-21 | Eagle Res Labs Limited | Dantrolene prodrugs and methods of their use |
| US11123328B2 (en) | 2017-11-14 | 2021-09-21 | University Health Network | Dantrolene and analogs thereof for the chronic treatment and prevention of dyssynchronous cardiac dysfunction |
| WO2019175761A1 (en) | 2018-03-12 | 2019-09-19 | Orbicular Pharmaceutical Technologies Private Limited | Ready to use dantrolene compositions |
| US12246028B2 (en) * | 2018-11-27 | 2025-03-11 | Eagle Research Labs Limited | Use of dantrolene and dantrolene prodrugs to treat radiation exposure |
| AU2021254415A1 (en) * | 2020-04-10 | 2022-10-20 | Eagle Pharmaceuticals, Inc. | Methods of treating Severe Acute Respiratory Syndrome |
-
2021
- 2021-04-08 US US17/995,602 patent/US12605364B2/en active Active
- 2021-04-08 BR BR112022020193A patent/BR112022020193A2/pt unknown
- 2021-04-08 EP EP21723473.1A patent/EP4132518B1/en active Active
- 2021-04-08 AU AU2021253866A patent/AU2021253866A1/en active Pending
- 2021-04-08 CN CN202180027309.8A patent/CN115361947A/zh active Pending
- 2021-04-08 CA CA3174710A patent/CA3174710A1/en active Pending
- 2021-04-08 KR KR1020227034976A patent/KR20230002371A/ko active Pending
- 2021-04-08 WO PCT/US2021/026302 patent/WO2021207443A1/en not_active Ceased
- 2021-04-08 MX MX2022012705A patent/MX2022012705A/es unknown
- 2021-04-08 IL IL296517A patent/IL296517A/en unknown
- 2021-04-08 JP JP2022561997A patent/JP2023521163A/ja active Pending
-
2022
- 2022-09-21 ZA ZA2022/10474A patent/ZA202210474B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115361947A (zh) | 2022-11-18 |
| KR20230002371A (ko) | 2023-01-05 |
| US20230144719A1 (en) | 2023-05-11 |
| MX2022012705A (es) | 2022-11-07 |
| WO2021207443A1 (en) | 2021-10-14 |
| AU2021253866A1 (en) | 2022-10-20 |
| JP2023521163A (ja) | 2023-05-23 |
| EP4132518A1 (en) | 2023-02-15 |
| IL296517A (en) | 2022-11-01 |
| US12605364B2 (en) | 2026-04-21 |
| EP4132518C0 (en) | 2025-08-13 |
| CA3174710A1 (en) | 2021-10-14 |
| BR112022020193A2 (pt) | 2022-11-22 |
| EP4132518B1 (en) | 2025-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| MX2024003952A (es) | Combinación que comprende atogepant para tratar la migraña. | |
| MX2023001071A (es) | Tratamiento de la migraña. | |
| PH12021553132A1 (en) | Methods of using rad51 inhibitors for treatment of pancreatic cancer | |
| WO2018102687A3 (en) | Combination therapy for treating cancer | |
| PH12018501712A1 (en) | Methods for treatment and prophylaxis of hiv and aids | |
| MX2024005107A (es) | Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer. | |
| ZA202212095B (en) | Il4i1 inhibitors and methods of use | |
| WO2023081830A3 (en) | Compositions and treatments with nirogacestat | |
| MX2019015212A (es) | Compuestos para el tratamiento del sarcoma. | |
| WO2021231931A8 (en) | Methods of treating sars-cov-2 infections | |
| MX2021012824A (es) | Métodos para tratar el prurito. | |
| EA201991688A1 (ru) | Фармацевтические комбинации для лечения рака | |
| WO2022015823A3 (en) | Methods for screening novel coronavirus antivirals and methods of using antivirals for the treatment of coronavirus infections | |
| ZA202210474B (en) | Methods of treating sars-cov-2 infections | |
| EA202092540A1 (ru) | Комбинации для лечения рака | |
| MX2022012632A (es) | Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington. | |
| PH12021551975A1 (en) | Use of vibegron to treat overactive bladder | |
| MX2021002590A (es) | Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor. | |
| ZA202103788B (en) | Use of dantrolene and dantrolene prodrugs to treat radiation exposure | |
| MX2024000634A (es) | Compuestos de sulfonimidamida y usos de los mismos. | |
| MY205171A (en) | Methods of treatment of hypertriglyceridemia | |
| MX2023012415A (es) | Metodos de uso del dantroleno para tratar la exposicion a agente nervioso. | |
| EA202193211A1 (ru) | Лечение синуклеопатий | |
| BR112022020107A2 (pt) | Métodos de tratamento da síndrome respiratória aguda grave |